Article
Medicine, Research & Experimental
Hui Hua, Jiajia Zeng, Haixin Xing, Yuxin He, Linyu Han, Nasha Zhang, Ming Yang
Summary: This study systematically evaluated the role of genetic variants in A-to-I editing genes on the prognosis of NSCLC patients receiving EGFR-TKIs therapy. The researchers identified several SNPs in the ADAR gene that were significantly associated with patient prognosis and found that silencing ADAR enhanced the sensitivity of NSCLC cells to gefitinib. These findings highlight the importance of A-to-I RNA editing in drug resistance and suggest ADAR as a potential therapeutic target for unresectable NSCLC.
Article
Medicine, Research & Experimental
Dan Yan, Justus M. Huelse, Dmitri Kireev, Zikang Tan, Luxiao Chen, Subir Goyal, Xiaodong Wang, Stephen Frye, Madhusmita Behera, Frank Schneider, Suresh S. Ramalingam, Taofeek Owonikoko, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham
Summary: Acquired resistance is inevitable in non-small cell lung cancers (NSCLCs) treated with osimertinib (OSI). Activation of MERTK is associated with OSI resistance and inhibition of MERTK kinase can resensitize resistant cells to OSI.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Oncology
Lingzhi Hong, Whitney E. Lewis, Monique Nilsson, Sonia Patel, Susan Varghese, Melvin J. Rivera, Robyn R. Du, Pingjun Chen, Haley N. Kemp, Waree Rinsurongkawong, Simon Heeke, Amy R. Spelman, Yasir Y. Elamin, Marcelo Negrao, Boris Sepesi, Don L. Gibbons, J. Jack Lee, Jia Wu, Natalie Vokes, John Heymach, Jianjun Zhang, Xiuning Le
Summary: The addition of anti-PD1 immunotherapy did not provide additional benefit to chemotherapy for EGFR-mutant LUAD patients with TKI resistance. However, there was a trend towards benefit with anti-VEGF therapy. The ideal choice for post-TKI treatment is still being evaluated.
Article
Biochemistry & Molecular Biology
Milena Casula, Marina Pisano, Panagiotis Paliogiannis, Maria Colombino, Maria Cristina Sini, Angelo Zinellu, Davide Santeufemia, Antonella Manca, Stefania Casula, Silvia Tore, Renato Lobrano, Antonio Cossu, Giuseppe Palmieri
Summary: Oncogenic mutations in the EGFR gene are targets of tyrosine kinase inhibitors in lung adenocarcinoma patients. Liquid biopsy of ctDNA is increasingly used to detect EGFR mutations. This study compared three different techniques and found that real-time PCR-based methods showed equivalent detection ability to the NGS assay for circulating EGFR mutations, but the NGS assay had a poor ability to detect T790M.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Hyoung-oh Jeong, Hayoon Lee, Hyemin Kim, Jinho Jang, Seunghoon Kim, Taejoo Hwang, David Whee-Young Choi, Hong Sook Kim, Naeun Lee, Yoo Mi Lee, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Semin Lee, Se-Hoon Lee
Summary: The study found that specific cell types such as lung epithelial precursor cells and transitional effector T cells, as well as an immunosuppressive microenvironment, were enriched in the MPE of EGFR TKI-resistant patients, potentially associated with their response to TKI therapy.
Article
Oncology
Pasi A. Janne, Christina Baik, Wu-Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A. Yu
Summary: HER3-DXd shows clinical activity in EGFR TKI-resistant lung cancer, regardless of resistance mechanisms, providing a new approach to treat drug-resistant cancers.
Article
Oncology
Soohyun Hwang, Tae Hee Hong, Sehhoon Park, Hyun-Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Yoon-La Choi, Se-Hoon Lee
Summary: This study evaluated the molecular characteristics of SCLCs transformed after EGFR TKI treatment, finding that the SCLC-N subtype was prevalent in the transformed SCLCs. Patients who transformed to the SCLC-A type had longer overall survival and time to transformation compared to those who transformed to SCLC-N or SCLC-TN. Large-scale data are needed to confirm these findings.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Geunho Choi, Daegeun Kim, Junehwan Oh
Summary: This study utilized artificial intelligence to discover potential drugs that can overcome acquired resistance in lung cancer patients, reducing the limitations of the current drug discovery process.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Zhengyu Yang, Ya Chen, Yanan Wang, Shuyuan Wang, Minjuan Hu, Bo Zhang, Baohui Han
Summary: In advanced lung adenocarcinoma patients, patients with concurrent TP53 mutations have a shorter time to disease progression with EGFR-TKI monotherapy, but TKI combined with chemotherapy can reduce this heterogeneity.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Daisy Wai-Ka Chan, Horace Cheuk-Wai Choi, Victor Ho-Fun Lee
Summary: This study conducted a systematic review and meta-analysis to investigate the treatment-related adverse events (trAEs) of combined epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) and immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer (NSCLC). The results demonstrated a higher incidence of grade >= 3 trAEs in combination TKI and ICI, particularly in skin, gastrointestinal tract, and interstitial lung diseases. However, the interpretation of these results should be cautious due to the limited number of studies included in this meta-analysis.
Article
Oncology
Jung Hee Cho, Yeon-Mi You, Han Koo, Dong Chul Lee, Young Il Yeom, Kyung Chan Park
Summary: This study identified LPIN1 as a key factor in regulating gefitinib resistance in EGFR-mutant NSCLC cells, and found that LPIN1 expression was induced following gefitinib treatment, leading to increased lipid droplet formation and activation of protein kinase C delta and nuclear factor kappa B. Targeting LPIN1 was shown to synergistically inhibit tumor growth, suggesting a potential effective strategy for preventing TKI resistance in NSCLC patients.
Article
Biochemistry & Molecular Biology
Sk. Kayum Alam, Yongchang Zhang, Li Wang, Zhu Zhu, Christina E. Hernandez, Yuling Zhou, Nong Yang, Jian Lei, Xiaoyan Chen, Liang Zeng, Mark A. Klein, Luke H. Hoeppner
Summary: The study reveals that DARPP-32 and kinase-activated EGFR and ERBB3 proteins are overexpressed in EGFR TKI-refractory LUAD, leading to the evasion of cell death through a specific mechanism.
Article
Oncology
James Chih-Hsin Yang, Yuichiro Ohe, Chao -Hua Chiu, Xiaoling Ou, Mireille Cantarini, Pasi A. Janne, Ryan J. Hartmaier, Myung Ju Ahn
Summary: The combination of osimertinib and selumetinib showed promising antitumor activity and tolerability in patients with MET-negative, EGFRm advanced NSCLC who had progressed on previous EGFR-TKI treatment.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Jon Apple, Rahul Shenolikar, Kevin De Silva, Ping Sun, Alexander Spira
Summary: This study evaluated the initiation of first-line therapy in EGFRm mNSCLC patients based on biomarker testing results. The results showed that EGFR TKIs as first-line therapy had better treatment outcomes compared to IO and chemotherapy.
Article
Oncology
Xiaoqian Zhai, Jiewei Liu, Zuoyu Liang, Zhixi Li, Yanyang Liu, Lin Huang, Weiya Wang, Feng Luo
Summary: This study proposed a new method for overcoming immunotherapy resistance after EGFR resistance in NSCLC patients with driver oncogene mutations, extending treatment options. Additionally, it is the first case to report that SCLC transformation can be achieved after gefitinib-pembrolizumab-gefitinib resistance in EGFR sensitive mutation NSCLC, providing a new condition for SCLC transformation.
FRONTIERS IN ONCOLOGY
(2021)
Article
Respiratory System
Johsuke Hara, Masaki Fujimura, Noriyuki Ohkura, Tamami Sakai, Kenta Yamamura, Miki Abo, Hayato Koba, Satoshi Watanabe, Taro Yoneda, Shingo Nishikawa, Takashi Sone, Hideharu Kimura, Yoshihisa Ishiura, Kazuo Kasahara
EXPERIMENTAL LUNG RESEARCH
(2017)
Article
Cardiac & Cardiovascular Systems
Satoshi Watanabe, Kazuo Kasahara, Yuko Waseda, Hazuki Takato, Shingo Nishikawa, Taro Yoneda, Johsuke Hara, Takashi Sone, Miki Abo, Hideharu Kimura, Shinji Nakao
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2017)
Letter
Dermatology
Akari Murata, Satoshi Watanabe, Yuka Ikawa, Keigo Saeki, Kenta Yamamura, Hiroki Matsuoka, Kota Tanimura, Yuichi Tambo, Kazuo Kasahara
JOURNAL OF DERMATOLOGY
(2019)
Review
Medicine, Research & Experimental
Satoshi Watanabe, Michael Alexander, Alexander V. Misharin, G. R. Scott Budinger
JOURNAL OF CLINICAL INVESTIGATION
(2019)
Article
Biochemistry & Molecular Biology
Paul Cheresh, Seok-Jo Kim, Long Shuang Huang, Satoshi Watanabe, Nikita Joshi, Kinola J. N. Williams, Monica Chi, Ziyan Lu, Anantha Harijith, Anjana Yeldandi, Anna P. Lam, Cara Gottardi, Alexander Misharin, G. R. Scott Budinger, Viswanathan Natarajan, David W. Kamp
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Article
Engineering, Biomedical
Satoshi Watanabe, Chitaru Kurihara, Adwaiy Manerikar, Sanket Thakkar, Mark Saine, Ankit Bharat
Summary: MELD score can be used complementarily to the RESP score to predict outcomes in patients with ARDS undergoing VV ECMO. Higher MELD score was associated with increased post-ECMO mortality but reduced risk of dialysis and tracheostomy.
Article
Medicine, Research & Experimental
Alexandra C. McQuattie-Pimentel, Ziyou Ren, Nikita Joshi, Satoshi Watanabe, Thomas Stoeger, Monica Chi, Ziyan Lu, Lango Sichizya, Raul Piseaux Aillon, Ching- Chen, Saul Soberanes, Zhangying Chen, Paul A. Reyfman, James M. Walter, Kishore R. Anekalla, Jennifer M. Davis, Kathryn A. Helmin, Constance E. Runyan, Hiam Abdala-Valencia, Kiwon Nam, Angelo Y. Meliton, Deborah R. Winter, Richard Morimoto, Gokhan M. Mutlu, Ankit Bharat, Harris Perlman, Cara J. Gottardi, Karen M. Ridge, Navdeep S. Chandel, Jacob Sznajder, William E. Balch, Benjamin D. Singer, Alexander Misharin, G. R. Scott Budinger
Summary: This study identified homogeneous age-related changes in the transcriptome of alveolar macrophages and demonstrated that the lung microenvironment affects the proliferation capacity of these cells, which in turn impacts the resistance of older patients to influenza viral infection. Targeting strategies towards the aging lung microenvironment may be necessary to restore alveolar macrophage function in aging individuals.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Multidisciplinary Sciences
Satoshi Watanabe, Nikolay S. Markov, Ziyan Lu, Raul Piseaux Aillon, Saul Soberanes, Constance E. Runyan, Ziyou Ren, Rogan A. Grant, Mariana Maciel, Hiam Abdala-Valencia, Yuliya Politanska, Kiwon Nam, Lango Sichizya, Hermon G. Kihshen, Nikita Joshi, Alexandra C. McQuattie-Pimentel, Katherine A. Gruner, Manu Jain, Jacob I. Sznajder, Richard I. Morimoto, Paul A. Reyfman, Cara J. Gottardi, G. R. Scott Budinger, Alexander V. Misharin
Summary: This study revealed that promoting the differentiation of AT2 cells into AT1 cells with ISRIB can accelerate epithelial repair, reduce the recruitment of profibrotic alveolar macrophages, and ameliorate lung fibrosis in the pathogenesis of pulmonary fibrosis.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Editorial Material
Critical Care Medicine
Takahiro Shimizu, Satoshi Watanabe, Akari Murata, Kazuo Kasahara
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2022)
Letter
Critical Care Medicine
Satoshi Watanabe, Kazuhiko Iwasaki, Kazuo Kasahara
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2022)
Article
Engineering, Biomedical
Adwaiy Manerikar, Satoshi Watanabe, Viswajit Kandula, Azad Karim, Sanket Thakkar, Mark Saine, Samuel S. Kim, Rafael Garza-Castillon, David D. Odell, Ankit Bharat, Chitaru Kurihara
Summary: BSI is a potentially lethal complication in patients receiving ECMO treatment. This study found that indwelling CVC, rather than the ECMO circuitry, is the likely contributor to BSI. Exchanging CVC by day 8 can reduce the incidence of BSI.
Article
Cardiac & Cardiovascular Systems
Satoshi Watanabe, Kazumasa Kase, Keigo Saeki, Noriyuki Ohkura, Akari Murata, Yuko Waseda, Hazuki Takato, Yukari Ichikawa, Masahide Yasui, Kazuo Kasahara
Summary: This study found that changes in KL-6 level can serve as a useful indicator for predicting disease progression in patients with SSc-ILD. Specifically, Delta KL-6 level greater than 193 U/mL and diffuse cutaneous SSc were identified as independent predictors for the progression of SSc-ILD.
RESPIRATORY MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Anthea Weng, Mariana Maciel Herrerias, Satoshi Watanabe, Lynn C. Welch, Annette S. Flozak, Rogan A. Grant, Raul Piseaux Aillon, Laura A. Dada, Seung Hye Han, Monique Hinchcliff, Alexander Misharin, G. R. Scott Budinger, Cara J. Gottardi
Summary: This study reveals that lung injury leads to hypertrophy and polyploidy of alveolar epithelial cells. The small molecule ISRIB can attenuate the hypertrophic and polyploid features of these cells. These findings suggest a potential link between alveolar epithelial injury and hypertrophic growth and polyploidization of the cells.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
(2022)
Editorial Material
Critical Care Medicine
Saya Tsukida, Satoshi Watanabe, Masato Hongo, Yuya Murase, Yoshihiro Yamamoto, Kazumasa Kase, Nanao Terada, Hayato Koba, Yuichi Tambo, Seiji Yano
Summary: A 71-year-old woman presented with a nonproductive cough. Examination revealed positive antinuclear antibodies and chest CT scan showed slight infiltrative shadow. Fiber optic bronchoscopy with BAL was performed to evaluate the possibility of interstitial pneumonia caused by Sjogren disease.
Article
Dermatology
Yasuhito Hamaguchi, Yukari Yoshimura, Motoki Horii, Natsumi Fushida, Tasuku Kitano, Kaori Sawada, Kyosuke Oishi, Shintaro Maeda, Satoshi Watanabe, Takashi Matsushita
Summary: Interstitial lung disease is a prognostic factor and leading cause of death in patients with systemic sclerosis. This study found that the presence of interstitial lung disease at an initial visit is an independent factor associated with disease deterioration.
JOURNAL OF DERMATOLOGY
(2023)
